Charles Schwab Investment Management Inc. Has $15.53 Million Stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Charles Schwab Investment Management Inc. raised its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 1.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 472,547 shares of the biopharmaceutical company’s stock after purchasing an additional 6,927 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Agios Pharmaceuticals were worth $15,528,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Venturi Wealth Management LLC acquired a new stake in shares of Agios Pharmaceuticals in the 4th quarter valued at about $33,000. Wingate Wealth Advisors Inc. acquired a new stake in shares of Agios Pharmaceuticals in the fourth quarter valued at about $53,000. KBC Group NV increased its position in shares of Agios Pharmaceuticals by 30.5% in the fourth quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock valued at $86,000 after acquiring an additional 611 shares during the last quarter. Quest Partners LLC increased its position in shares of Agios Pharmaceuticals by 139.6% in the third quarter. Quest Partners LLC now owns 2,202 shares of the biopharmaceutical company’s stock valued at $98,000 after acquiring an additional 1,283 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new stake in shares of Agios Pharmaceuticals in the third quarter valued at about $146,000.

Agios Pharmaceuticals Stock Performance

Agios Pharmaceuticals stock opened at $32.71 on Friday. Agios Pharmaceuticals, Inc. has a 52 week low of $27.14 and a 52 week high of $62.58. The stock has a market capitalization of $1.87 billion, a P/E ratio of 2.88 and a beta of 0.90. The stock has a 50-day simple moving average of $33.44 and a 200 day simple moving average of $41.43.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. Research analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Insider Transactions at Agios Pharmaceuticals

In other news, insider Tsveta Milanova sold 2,804 shares of Agios Pharmaceuticals stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $32.18, for a total value of $90,232.72. Following the completion of the sale, the insider now directly owns 18,906 shares in the company, valued at approximately $608,395.08. The trade was a 12.92 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 4.93% of the company’s stock.

Analyst Upgrades and Downgrades

AGIO has been the topic of a number of recent research reports. StockNews.com downgraded Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, February 14th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. Scotiabank lifted their target price on Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a research report on Monday, December 9th. HC Wainwright initiated coverage on Agios Pharmaceuticals in a research report on Monday, February 24th. They issued a “buy” rating and a $58.00 target price on the stock. Finally, Royal Bank of Canada lifted their price target on Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $56.57.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.